丙型肝炎直接抗病毒药物的发展现状

Status quo and progress in the development of direct-acting antiviral agents against hepatitis C

慢性丙型肝炎的标准化治疗方案为聚乙二醇IFN联合利巴韦林，但其疗效欠佳，而口服直接抗病毒药物（DAA）的问世给患者带来了新的希望。目前已经上市或在研的DAA主要包括NS3／4A蛋白酶抑制剂、NS5A蛋白酶抑制剂和NS5B聚合酶抑制剂等。此文对这3种DAA的发展现状及其进展作一综述。

Pegylated-interferon combined with ribavirin is considered as the standard treatment of chronic hepatitis C , but the efficacy is limited. The advent of direct-acting antiviral agents （DAAs）brings new hope to patients infected with HCV. DAAs on the market or under research can be mainly classified into NS3/4A protease inhibitors, NS5A protease inhibitors, and NSSB polymerase inhibitors. This article reviews the progress in the development of DAAs.